Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alka Dwivedi

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Molecular Therapy. Methods & Clinical Development|February 1, 2024
Manufacture of CD22 CAR T cells following positive versus negative selection results in distinct cytokine secretion profiles and γδ T cell outputHannah W Song, Mehdi Benzaoui, Alka Dwivedi, et al.
Molecular Cancer Therapeutics|February 26, 2021
Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T CellsAlka Dwivedi, Atharva Karulkar, Sarbari Ghosh, et al.
American Journal of Medical Genetics. Part A|December 5, 2012
Clinical utility of the X-chromosome arrayYuri A Zarate, Alka Dwivedi, Frank O Bartel, et al.
Cell|April 12, 2025
Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificityTaisuke Kondo, François X P Bourassa, Sooraj Achar, et al.
The Lancet. Haematology|March 16, 2025
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 studyHasmukh Jain, Atharva Karulkar, Devanshi Kalra, et al.
Blood Cancer Journal|May 20, 2025
Correction: Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib studyGaurav Narula, Swaminathan Keerthivasagam, Hasmukh Jain, et al.
Blood Cancer Journal|April 24, 2025
Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib studyGaurav Narula, Swaminathan Keerthivasagam, Hasmukh Jain, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Molecular Therapy. Methods & Clinical Development|February 1, 2024
Manufacture of CD22 CAR T cells following positive versus negative selection results in distinct cytokine secretion profiles and γδ T cell outputHannah W Song, Mehdi Benzaoui, Alka Dwivedi, et al.
Molecular Cancer Therapeutics|February 26, 2021
Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T CellsAlka Dwivedi, Atharva Karulkar, Sarbari Ghosh, et al.
American Journal of Medical Genetics. Part A|December 5, 2012
Clinical utility of the X-chromosome arrayYuri A Zarate, Alka Dwivedi, Frank O Bartel, et al.
Cell|April 12, 2025
Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificityTaisuke Kondo, François X P Bourassa, Sooraj Achar, et al.
The Lancet. Haematology|March 16, 2025
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 studyHasmukh Jain, Atharva Karulkar, Devanshi Kalra, et al.
Blood Cancer Journal|May 20, 2025
Correction: Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib studyGaurav Narula, Swaminathan Keerthivasagam, Hasmukh Jain, et al.
Blood Cancer Journal|April 24, 2025
Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib studyGaurav Narula, Swaminathan Keerthivasagam, Hasmukh Jain, et al.
Pageof 4